Journal of medical biochemistry · 2025
Assessment of prognostic risk of death in patients with multiple myeloma based on CD184 and CD269: A retrospective analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Hong, Zhao Yuan, Zhang Zhiyu, Xie Yan, Jin Mulan
Аннотация
BACKGROUND: This study aimed to analyze the expressions of CD184 and CD269 in patients with newly diagnosed multiple myeloma (MM) in China and explored their potential association with prognosis.
METHODS: This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves.
RESULTS: Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P<0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P<0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients.
CONCLUSIONS: CD184 and CD269 may serve as valuable prognostic markers in MM patients.
METHODS: This retrospective study recruited 100 patients with MM and 113 healthy controls who attended Beijing Chaoyang Hospital Shijingshan District between June 2020 and December 2023. The association between CD184 and CD269 expression and patient survival outcomes was assessed using univariable and multivariable Cox proportional hazards regression analyses, alongside Kaplan-Meier survival curves.
RESULTS: Both CD184 and CD269 mRNA were elevated in MM patients compared to controls (P<0.05). By qualitative analysis, it was seen that both CD184+ and CD269 patients had a reduced prognostic overall survival (OS) (P<0.05). Similarly, detection of CD184 and CD269 expression was effective in predicting prognostic mortality in patients.
CONCLUSIONS: CD184 and CD269 may serve as valuable prognostic markers in MM patients.